Financial Highlights – Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR) – Q3 Performance Snapshot

• Revenue Growth: Reported revenue of ₹251 crore in Q3, marking a 47% YoY increase from ₹171 crore.
• Profit Expansion: Profit after tax rose 50% YoY to ₹66.5 crore, compared with ₹44.3 crore in the same quarter last year.
• Margin Movement: EBITDA margin moderated to 8%, versus 36.5% in the year-ago period.
• Dividend Announcement: Declared a dividend of ₹75 per share.
• Operational Momentum: Earnings growth outpaced revenue expansion, reflecting improved scale and cost management despite slight margin compression.

Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR)

Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR) rose 4.66% to ₹4,777.00 on 27 February 2026, extending its recent upward trajectory following encouraging quarterly performance. The company operates in the consumer healthcare space, offering vitamins, nutritional supplements, and over-the-counter wellness products across India. Steady demand across core brands, improving scale efficiencies, and disciplined cost management supported revenue growth during the period. Strong return ratios and healthy cash generation underscore operational stability. Although margin pressure from higher input costs remains a monitorable factor, diversified product offerings and sustained domestic consumption trends continue to provide structural support to overall performance.

Sanofi Consumer Posts Strong Quarterly Performance, Declares Dividend

Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR) delivered a robust quarterly performance, supported by strong revenue expansion and healthy profit growth compared with the previous year. The company maintained solid operational momentum across its key consumer healthcare brands, reflecting steady domestic demand and effective execution. While margins moderated slightly amid input cost pressures, overall profitability remained resilient. The board also announced a dividend payout, reinforcing confidence in cash flow strength and balance sheet stability. Continued brand traction and distribution reach remain central to its growth outlook.

Technical View: Sanofi Consumer Above 50-Day SMA – Breakout or Pause?

From a technical perspective, Sanofi Consumer Healthcare India Limited has witnessed a sharp upward move, with the stock trading at ₹4,777.00, significantly above its 50-day Simple Moving Average at ₹4,294.53, reinforcing an improving near-term structure. The strong bullish candle suggests renewed buying interest after a prolonged corrective phase. The 14-day RSI at 70.94 indicates elevated momentum conditions, pointing to stretched levels that may invite short-term consolidation. Immediate support is placed near ₹4,200.00 and ₹3,800.00, while resistance is seen around ₹5,350.00 and ₹6,000.00.

Bottom Line: SANOFICONR’s Earnings Momentum vs Margin Watch — What Ahead?

Sanofi Consumer Healthcare India Limited has shown steady earnings improvement and stable operational performance, supporting recent price movement. However, margin moderation and input cost trends remain important factors to watch. Near-term direction may depend on demand consistency, cost management, and the stock’s ability to hold above key technical levels.